Anti-CD3 monoclonal antibodies

Bertotto, A., et al. Activation of cord T lymphocytes. II. Cellular and molecular analysis of the defective response induced by anti-CD3 monoclonal antibody, Cell. Immunol., 127, 247, 1990. 

Alegre, M., Depierreux, M., Florquin, S., Najdovski, T., Vandenabeele, P., Abramowicz, D., Leo, O., Deschodt-Lanckman, M. and Goldman, M. (1990) Acute toxicity of Anti-CD3 monoclonal antibody in mice a model for OKT3 first dose reactions. Transplantation Proceedings, 22, 1920-1921. 

Recently, biologicals such as anti-CD3 monoclonal antibody have been used to combat acute rejection. Chronic rejection usually occurs months or even years after transplantation. It is characterized by thickening and fibrosis of the vasculature of the transplanted organ, involving both cellular and humoral immunity. Chronic rejection is treated with the same drugs as those used for acute rejection. 

Parren PW, Warmerdam PA, Boeije FC, Capel PJ, van de Winkel JG, Aarden LA. Characterization of IgG FcR-mediated prohferation Of human T cells induced by mouse and Human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. J Immunol 1992 148(3) 695-701. 

OKT3 anti-CD3 monoclonal antibody PTCA percutanerous transluminal coronary angio-... 

Jenkins, M.K., Chen, C., Jung, G., Mueller, D.L. and Schwartz, R.H. (1990). Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 144, 16-22. 

Abramowicz D, Wissing M, Breeders N. Induction with anti-CD3 monoclonal antibodies. Current Opin Organ Transplant 1999 4 312-317. 

Alegre M, Vandenabeele P, Flamand V, Moser M, Leo O, Abramowicz D, Urbain J, Piers W, Goldman M. Elypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice role of tumor necrosis factor. Eur J Immunol 1990 20(3) 707-710. 

Mackie JD, Pankewycz OG, Bastos MG, Kelley VE, Strom TB. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed-type hypersensitivity. Transplantation 1990 49(6) 1150-1154. 

Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach JF et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody further evidence for transient in vivo T cell activation. Eur J... 

Anti-CD3 Monoclonal Antibodies Antibodies directed at the e chain of CD3, a trimeric molecule adjacent to the T-ceU receptor on the surface of human T lymphocytes, have been used with considerable efficacy in human transplantation. The original mouse IgG, antihuman CDS monoclonal antibody, muromonab-CD3 (OKT3, ORTHOCLONE okt3), stiU is used to reverse glucocorticoid-resistant rejection episodes. 

Bemelmans, H. A., Abramowicz, D., Gouma, D. J., Goldman, M., and Buurman, W. A. (1994). In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. /. Immunol. 153, 499-506. 

However, the development of OKT3 and other anti-CD3 monoclonal antibodies was hampered by serious adverse reactions associated with cytokine storm, as a consequence of generalized T-cell activation [76 ]. 

Visilizumab is a humanized anti-CD3 monoclonal antibody characterized by a mutated IgG2 isotype, lack of binding to Fey receptors, and an ability to induce apoptosis selectively in activated T cells. 

Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandbom W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007 133(5) 1414-22. 

---